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Suramin, a non-specific growth factor antagonist, is currently 
under investigation for treatment of cancer patients. We stud- 
ied its action on 6 different human breast-cancer cell lines in 
vitro. In complete growth medium, pleiotropic effects were 
observed with respect to cell proliferation, i.e. suramin is 
stimulatory at low concentrations and inhibitory at higher 
concentrations, for 4 of the 6 cell lines studied. The various cell 
lines showed marked differences with respect to the antiprolif- 
erative action of suramin, the Evsa-T cells being by far the most 
sensitive ones. A suramin concentration of 100 pg/ml brought 
about a 100% stimulation of the proliferation of ZR/HERc cells, 
ZR 75. I cells ectopically expressing a human epidermal growth 
factor receptor (EGF-R) cDNA. Although less pronounced (I 0 
to 60% stimulation), a similar response was observed for the 
parent ZR 75.1 cells, as well as for T-47D and MDA-MB-231 
cells. The non-specificity of the action of suramin was estab- 
lished by the observation that suramin-induced inhibition of cell 
proliferation could be abolished by insulin-like growth factor- I 
(IGF- I) or basic fibroblast growth factor (bFGF), and even by 
estradiol, both in complete growth medium and under defined 
serum-free conditions. Our data indicate that suramin exerts 
pleiotropic effects on the proliferation of human breast cancer 
cells in vitro, and confirm the non-specific nature of i ts  action. 
The stimulatory effect of low concentrations of suramin on the 
proliferation of breast cancer cells may have important conse- 
quences for breast cancer patients treated with surarnin. 
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Hormones and growth factors play an important role in the 
growth regulation of several tumors, such as breast, prostate 
and endometrial cancer. Hormones may exert their action 
through interference with the production of a variety of growth 
factors and/or their receptors. Moreover, abnormal growth 
factor secretion or abnormal growth factor receptor levels may 
underlie the development of hormone-independence. Amplifi- 
cation of some (0nco)genes or overexpression of their protein 
products in tumor cells, especially of HER2/neu and epider- 
mal growth factor receptor (EGF-R), may be of prognostic 
significance for cancer patients, although no general statement 
with respect to the prognostic implications for specific sub- 
classes of breast cancer patients can be made as yet (Gullick, 
1990; Klijn et al., 1992). In contrast to the availability of many 
different hormonal therapies, treatment modalities affecting 
(onco)gencs, growth factors, or growth-factor receptors are 
practically unavailable. One of the potential treatment modal- 
ities based upon the interaction of growth factors with their 
receptors may involve specific growth-factor antagonists. How- 
ever, such antagonists are not yet available for the growth 
factors known to be involved in breast-cancer regulation. As a 
non-specific growth factor antagonist, suramin (a polysulpho- 
nated naphthylurea) for use in the treatment of patients with 
metastatic cancer has attracted much attention in recent years. 
Promising results have been obtained in patients with adrenal 
and prostate cancer, and in patients with heavily pretreated 
non-Hodgkin’s lymphoma (Stein et al., 1989; Vierhapper et al., 
1989; LaRocca et al., 1990). Suramin or (functionally) related 
compounds could, therefore, become of increasing importance 
in clinical practice. 
In preclinical studies, suramin has been shown to exert an 
antiproliferative effect on a variety of human cancer cell lines 
grown in vitro. These lines include breast, prostate, head and 
neck, bladder, ovary, lung and colon cancer cells, as well as 
melanoma, osteosarcoma, glioblastoma and lymphoid cells 
(Betsholtz et al., 1984; Coffey et al., 1987; Spigelman et al., 
1987; Forgue-Lafitte et al., 1989; LaRocca et al., 1990; Klijn et 
al., 1990; Olivier et al., 1990; Berns et al., 1990). It has been 
postulated that suramin has mainly extracellular effects (Bet- 
sholtz et al., 1984; Coffey et al., 1987), but direct intracellular 
effects cannot be excluded (Spigelman et al., 1987). The 
principal mechanism through which suramin acts is probably 
via interference with the interaction of growth factors and 
their receptors, and as a result in their signal transduction 
pathways. The efficacy of suramin in blocking the binding of a 
variety of growth factors to their specific cell-surface receptors 
has been shown to vary. These growth factors include platelet- 
derived growth factor (PDGF) (Betsholtz et al., 1984; Garrett 
et al., 1984), epidermal growth factor (EGF) (Coffey et al., 
1987; Berns et al., 1990), transforming growth factor+ (TGF-P) 
(Coffey et al., 1987), acidic (Coughlin et al., 1988) and basic 
(Coffey et al., 1987; Coughlin et al., 1988) fibroblast growth 
factor (aFGF and bFGF), insulin-like growth factor-1 (IGF-1) 
(Pollak and Richard, 1990) and interleukin-2 (IL-2) (Mills et 
al., 1990). Because of the growing interest in suramin and 
suramin-like compounds as anticancer drugs, and because of 
the possible biphasic effects suramin can generate on prolifer- 
ation of cancer cells in vitro, (i.e. stimulatory at low concentra- 
tions and inhibitory at higher concentrations) (Berns et al., 
1990; Olivier et al., 1990), we have studied its effects on the 
proliferation of a variety of human breast-cancer cell lines in 
vitro. To shed some light on the possible mode(s) of action, cell 
lines with different steroid receptor and growth factor receptor 
phenotypes were used. We observed a pleiotropic action of 
suramin with respect to (anti)proliferative effects. Possible 
unwanted consequences of the treatment of breast-cancer 
patients with suramin will be discussed. 
MATERIAL AND METHODS 
Material 
Suramin, the hexasodium salt of 8,8’-[carbonylbis[imino-3,1- 
phenylenecarbamylimino(4-methyl-2,l-phenylene) carbonyl- 
imino]]bis-1,3,5-naphthalenetrisulfonic acid, was purchased 
from FBA, Bayer, Leverkusen, Germany. Insulin-like growth 
factor-1 (IGF-1) was a generous gift of Dr. K. Miiller (Ciba- 
Geigy, Basel, Switzerland). Epidermal growth factor (EGF) 
and basic fibroblast growth factor (bFGF) were purchased 
from BTI (Stoughton, MA). Culture media were obtained 
from Sigma (St. Louis, MO), penicillin/streptomycin and 
trypsin from Northumbria Biologicals (Cramlington, UK), 
porcine insulin from Organon (Oss, The Netherlands), genta- 
micin from Sebak (Aidenbach, Germany), and FCS and iron- 
supplemented bovine calf serum from HyClone (Logan, UT). 
MCF-7 (ER+/PgR+), MDA-MB-231 (ER-PgR-), and 
T-47D (ER’/PgR+) cells, were obtained from the ATCC 
(Rockville, MD). ZR 75.1 cells (ER+/PgR+) were a gift from 
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Dr. R.J.B. King (ICRF, London, UK). Evsa-T cells (ER-/ 
PgR-) were a gift from Dr. N. DeVleeschouwer (Institut Jules 
Bordet, Brussels, Belgium). ZR/HERc cells (ER+/PgR+) 
originated from ZR 75.1 cells after introduction of the human 
EGF-R cDNA utilizing a retroviral factor (Dorssers et al., 
1991). MTT [3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazoli- 
umbromide] was supplied by (Sigma). 
Cell culture 
Cells were routinely grown in their respective complete 
growth medium. For T-47D cells: RPMI-1640 medium, contain- 
ing phenol red and 10% heat-inactivated (30 min at 56°C) 
bovine calf serum, NaHCO3 (10 mM), HEPES (20 mM), 
glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 
pg/ml), and gentamicin (45 pg/ml) was used. For routine 
culture of MCF-7 and T-47D cells this medium was supple- 
mented with 10 pg/ml porcine insulin, and for ZR 75.1 and 
ZR/HERc cells it was supplemented with 1 nM estradiol. 
Complete growth medium for Evsa-T cells consisted of DMEMi 
HAM-F12 medium, containing phenol red and 14 mM HEPES, 
and supplemented with the same additives as for routine 
MCF-7 cell culture, except that 5% heat-inactivated bovine 
calf serum was added. MDA-MB-231 cells were routinely 
cultured in the same medium as MCF-7 cells, except that 
DMEM/HAM F-12 medium containing 14 mM HEPES was 
used instead of RPMI-1640 medium. 
For experiments in a chemically defined medium, medium 
consisted of DMEM/HAM F-12 medium (without phenol 
red), supplemented with NaHC03 (10 mM), HEPES (15 mM), 
glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 
pg/ml), gentamicin (45 pg/ml), 0.2% bovine serum albumin 
(BSA, purified, Behringwerke, Marburg, Germany), and 
NazSe203 (50 ng/ml) (=serum-free medium: SFM). 
Cell proliferation assay 
Cells were harvested by trypsinization, resuspended in fresh 
medium in 96-well microtiter plates (Greiner, Alphen/Rhine, 
The Netherlands) and incubated for the time indicated in the 
Figure legends to allow attachment and flattening of the cells, 
after which experimental medium containing the respective 
additives was added. Following incubations (8 wells for each 
condition studied), and for the time periods indicated in the 
Figure legends, the MTT assay (Carmichael et al., 1987) was 
used to evaluate the effects of the various additives on cell 
proliferation. For the cell lines used we established a linear 
relation between the MTT-assay and cell number within the 
range of the experiments shown. Since the presence of suramin 
in the medium reduced formazan production in the MTT assay 
in a dose-dependent way, the wells were washed twice with 
PBS before experimental medium without drugs, but contain- 
ing MTT (0.65 mg/ml), was added for 4 hr. Possible remaining 
amounts of suramin attached to the cells after washing did not 
interfere in the MTT assay, as was established by comparing 
cell counts and absorbance at 510 nm before and after 
washing. Subsequently, 100 kl DMSO was added to each 
aspirated well, the plates were shaken for 10 min, and the 
optical density at 510 nm was read on an automatic microplate 
reader (Titertec, Flow, Irvine, UK). 
IGF-1-R and EGF-R assay 
Cells were grown in 75-cm2 flasks in complete growth 
medium until approximately 75% confluence was reached. 
Cells were rinsed twice with PBS, and further incubated for 
2 x 1 hr in SFM before harvesting by a 2-min incubation at 
20°C with 0.01% trypsin/0.004% EDTA. This brief trypsin 
treatment did not affect the amount of measurable growth 
factor receptor in ligand binding assays. 
For the IGF-1-R assay, 500,000 cells per conical 1.5-ml 
Eppendorf tube were incubated in a final volume of 200 pl 
SFM with increasing concentrations (range 0.1 to 1.5 nM) of 
[1251]IGF-1 (spec.act. 2,000 Ci/mmol: h~man-Thr~~-analog, 
Amersham, Aylesbury, UK), in the absence or presence of a 
200-fold excess of non-radioactive IGF-1 to correct for non- 
specific binding. Following incubation for 20 hr at 4"C, cells 
were washed 3 times with 1 ml PBS at 4°C and centrifuged for 5 
min at 800 g. Cell-bound radioactivity associated with the 
pellet fraction was counted in a Cobra 5005 gamma-counter 
(Canberra Packard, Tilburg, The Netherlands) with 80% 
efficiency. 
For the EGF-R assay, cells were homogenized with a 
microdismembrator at - 196°C according to procedures de- 
scribed by the EORTC for homogenization of human breast 
tumors (EORTC Breast Cancer Cooperative Group, 1980). 
The 100,000 g pellet fraction was prepared as described 
(EORTC Breast Cancer Cooperative Group, 1980) and re- 
homogenized in 1.5 ml buffer A (0.02 M phosphate buffer, pH 
7.4, containing 0.15 M NaCl and 70 pg/ml bacitracin) with 2 X 
5-sec bursts of an Omni-1,000 tissue homogenizer (Omni, 
Waterbury, CT). The homogenate was centrifuged for 10 min 
at 1,000 g and the resulting supernatant fraction was used as 
membrane preparation. Membrane preparations (100 1.1) 
were incubated for 20 hr at 20°C in a final volume of 140 p1 
buffer B (buffer A containing 0.1% BSA) with increasing 
concentrations (0.1 to 2 nM) of [1251]EGF [spec. act. 500 
Ci/mmol: mouse-EGF, receptor grade (Sigma), radiolabeled 
with Protag 125 (J.T. Baker, Philipsburg, NJ), as described by 
Benraad and Foekens, (1990) in the absence or presence of a 
200-fold excess of non-radioactive EGF to correct for non- 
specific binding. Separation of bound and free ligand was 
performed at 20°C by hydroxylapatite (HAP) adsorption of 
EGF-R and washing away of the non-bound ligand with buffer 
A (Benraad and Foekens, 1990). HAP-bound radioactivity was 
counted. 
RESULTS 
Reversible effects of surumin in complete growth medium 
Suramin had a dose-dependent effect on the proliferation of 
human breast-cancer cell lines. For 4 of the 6 cell lines tested 
this effect of suramin was biphasic, i.e. stimulatory at low 
concentrations and inhibitory at higher concentrations (Fig. 
1). The Figure further shows that the various cell lines display 
different sensitivities towards suramin, the Evsa-T cell line 
being by far the most sensitive to the inhibitory effects 
(IC5,, = 87 pg/ml of suramin) and the ZR/HERc cells being 
the most sensitive to the stimulatory effects of suramin. 
To study possible reversible effects of suramin on cell 
proliferation, cells were cultured in the presence of inhibitory 
concentrations of 1.0 mg/ml suramin. After 3 days of culture, 
cells were allowed to further proliferate in the absence or 
presence of suramin for 6 days. Figure 2 shows that MCF-7, 
MDA-MB-231 and Evsa-T cells resumed growth after initial 
inhibition of cell proliferation at day 3, and prolonged culture 
in the absence of suramin. Again, the various cell lines 
displayed different sensitivities towards suramin, MDA-MB- 
231 cells being the least sensitive and Evsa-T cells being the 
most sensitive. Cultures lacking suramin during the last 6 days 
of culture after an initial exposure to suramin showed rapid 
regrowth of MDA-MB-321 cells, while growth of MCF-7 and 
Evsa-T cells did not recover after a 3-day exposure to 1 mg/ml 
suramin (Fig. 2). Experiments with exposure to lower concen- 
trations of suramin (0.1, 0.25 and 0.5 mg/ml) also showed for 
MCF-7 and for Evsa-T cells a regrowth of the cells (not 
shown). After pre-exposure of the cells to these lower concen- 
trations of suramin, restoration of proliferation was more 
pronounced since the cell number, i.e. the absorbance at 510 
nm measured at day 9, was higher than that of control cultures 
at day 3 (data not shown). This was not the case for MCF-7 and 
Evsa-T cells after a 3-day exposure to the high concentration of 
1.0 mg/ml suramin (Fig. 2). Reversibility of the effects of 
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FIGURE 1 - Dose-response effect of suramin on proliferation of 
human breast cancer cells in vitro. Cells were plated at a density of 
5,000 cells/200 pl (for T-47D cells, 7,500 cells/200 p1) in their 
respective complete growth medium. After 24 hr, medium was 
replaced by complete growth medium with and without the 
addition of various concentrations of suramin (ranging from 0.016 
to 0.55 mg/ml). Medium was renewed after 3 days. After 5 days of 
continuous drug ex osure, the MTT assay was performed. (a) 
ZR/HERc cells (----p, ZR 75.1 cells (-- , and T-47D cells (-). (b) 
MDA-MB-231 cells (----), MCF-7 cells (--), and Evsa-T cells (-). 
The results are depicted as the fraction of control-cell prolifera- 
tion 2 standard error of the quotient vs. suramin concentration. 
1.50 , 1 
000 u 
MCF-7 MDA-MB-231 Evsa-T 
FIGURE 2 - Reversible effect of suramin on proliferation of 
human breast-cancer cells in vitro. Cells were plated at a density of 
5,000 cells/200 pl and cultured for 3 days in their respective 
complete growth medium with or without (control) the addition of 
1.0 mg/ml suramin. After 3 days the MTT assay was performed on 
control and suramin-containing cultures. In parallel cultures, 
suramin was washed away-after 3 days’ preincubation with 
suramin-with 2 washes of complete growth medium, and the cells 
were allowed to proliferate for 6 more days in the presence or 
absence of suramin before the M l T  assay was performed. Results 
are expressed as the mean absorbance at 510 nm 2 SD of 
suramin-lacking control cultures at day 3 ( ), suramin-containing 
cultures at day 3 (El), suramin-containing ultures at day 9 (O), 
and cultures lacking suramin during the last 6 days of culture after 
an initial 3-day exposure to suramin, i.e. at day 9 ( 
suramin was also observed for the other 3 breast-cancer cell 
lines tested (ZR 75.1,ZR/HERc and T-47D). 
Effects of suramin in serum-free medium 
Under serum-free conditions both estradiol and insulin-like 
growth factor-1 (IGF-1) were potent mitogens for MCF-7 cells 
(Fig. 3a). The growth of stimulated and non-stimulated cul- 
tures was inhibited by suramin in a dose-dependent way. 
Moreover, in serum-free medium (SFM) the net inhibitory 
effect on cell proliferation, at concentrations of suramin as 
high as 0.5 mg/ml, could be partly overruled by the simulta- 
neous addition of estradiol or IGF-1 to the cultures (Fig. 3a). 
At lower concentrations of suramin (0.1 and 0.25 mg/ml) 
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FIGURE 3 - Effect of suramin on proliferation of stimulated and 
non-stimulated MCF-7 cell cultures in serum-free medium (SFM). 
MCF-7 cells were plated at a density of 10,000 cells/200 pl (a) or 
5,000 cells/200 p1 (b) in complete growth medium, and allowed to 
attach and flatten for 4 hr. Following 2 washings with PBS, cells 
were cultured for 6 days in SFM in the absence or presence of 
increasing concentrations of suramin and/or estradiol, IGF-1, and 
bFGF. (a) Control (-), estradiol (0.01 nM, --; 1.0 nM, -----), 
IGF-1 (1 ng/ml, -.-; 100 ng/ml, (b) bFGF (0 ng/ml, -; 1 
ngiml, --; 10 ng/ml, -----; 100 ng/ml, -.-). The M l T  assay was 
performed after 6 days of culture, and results are depicted as the 
fraction of control-cell proliferation f standard error of the 
uotient in the absence of suramin, hormone and growth factors ? the horizontal dotted lines) vs. suramin concentration (a, linear 
scale; b, logarithmic scale). 
IGF-1 and/or estradiol were still able to stimulate cell prolifer- 
ation, even when compared to cultures without suramin (up to 
100% stimulation by 1 nM estradiol in the presence of 0.1 
mg/ml suramin; Fig. 3a). A similar occurrence was observed in 
subsequent experiments in which MCF-7 cells were cultured in 
SFM in the absence or presence of increasing concentrations 
of basic-fibroblast growth factor (bFGF). Concentrations of 
bFGF as low as 1 ng/ml stimulated cell proliferation by 200% 
when compared to control cultures at day 6 (Fig. 3b). Higher 
concentrations of 10 and 100 ng/ml bFGF were unable to 
further stimulate cell proliferation. Suramin inhibited both the 
b-FGF-stimulated and the basal MCF-7 cell proliferation in a 
dose-dependent manner. The 200% stimulation caused by 1 
ng/ml bFGF was reduced to only 120% by concentrations of 
suramin as low as 0.01 mg/ml. However, suramin at  a concen- 
tration of 0.01 mg/ml was not able to inhibit the bFGF- 
stimulated proliferation caused by higher concentrations (10 
and 100 ng/ml) of bFGF (Fig. 3b). At the intermediate 
suramin concentration of 0.1 mg/ml net stimulatory effects 
caused by bFGF (up to 43% stimulation) were still observed. 
In the presence of 1.0 mg/ml suramin, bFGF was no longer 
able to stimulate cell proliferation or abolish the suramin- 
induced inhibition, and a net inhibitory effect (+60% inhibi- 
tion) was observed in both the absence and presence of bFGF 
up to 100 ng/ml (Fig. 3b). 
Effects of hormones and growth factors on suramin action 
To gain more insight into the specificity of suramin action, 
MCF-7 cells (IGF-1-R positive: Fig. 4, left), ZR 75.1 cells 
(EGF-R negative: data not shown), and ZR/HERc cells (ZR 
75.1 cells ectopically expressing the human EGF-R cDNA, 
EGF-R-positive: Fig. 4, right), were cultured in complete 
growth medium in the absence or presence of increasing 
concentrations of suramin and/or IGF-1 (MCF-7; Fig. 5a) 
and/or estradiol (MCF-7; Fig. 5b), and/or E G F  (ZR 75.1; Fig. 
5c, and ZR/HERc;  Fig. 5d). In contrast to what was observed 
in serum-free medium with slowly proliferating cells (Fig. 3a), 
in the absence of suramin, neither IGF-1 at concentrations up 
to 10 p,g/ml nor estradiol affected the already maximally 
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RCURE 4-Scatchard analysis of IGF-1 and EGF binding. 
MCF-7 and ZR/HERc cells were cultured 75-cm2 flasks in 
complete growth medium to approximatel 75% confluence. 
lZI-IGF-l (MCF-7 cells; left panel) and 12&-EGF (ZR/HERc 
cells; right panel) binding studies were performed as described in 
the text. Specific binding is plotted. The number of specific 
IZI-IGF-1 binding sites was 2.8 x lo4 molecules/cell (k: 0.4 nM), 
and the amount of lZ5I-EGF binding sites was 207 fmol/mg 
membrane protein (k: 0.9 nM). 
proliferating MCF-7 cells in complete growth medium (Fig. 5a 
and b, respectively). However, the net inhibition of cell 
proliferation caused by 0.1 and 0.25 mg/ml of suramin (15% 
and 45%, respectively) was completely abolished by IGF-1 in a 
dose-dependent manner (Fig. 5a), or by estradiol which 
however displayed a less dose-dependent relationship (Fig. 
5b). Inhibition of cell proliferation caused by 0.5 mg/ml of 
suramin (70% inhibition) could only partially be overcome by 
the concentrations of IGF-1 or estradiol used (Fig. 5a, b). The 
intermediate concentration of suramin used (0.1 mg/ml) 
caused a 40% stimulation of ZR 75.1 cells over basal prolifera- 
tion in complete growth medium (Fig. 5c), an occurrence 
which was also shown in Figure lb  where twice the amount of 
cells were originally plated. Surprisingly, however, in the 
presence of the lowest concentration of suramin used (0.03 
mg/ml), EGF was able to stimulate the proliferation of the 
EGF-R-negative ZR 75.1 cells (up to 40% stimulation; Fig. 
5c). EGF had no effect on the suramin-induced inhibition (at 
0.3 mg/ml) or stimulation (at 0.1 mg/ml) of proliferation of the 
EGF-R-negative ZR 75.1 cells, nor on the basal proliferation. 
The ZR 75.1 cells which were virally infected with EGF-R 
cDNA, the ZR/HERc cells, showed a marked stimulation of 
proliferation (30% and 55%) by the 2 lowest concentrations of 
suramin used (0.03 and 0.1 mg/ml; Fig. 5 4 .  The basal 
proliferation of the EGF-R-positive ZR/HERc cells in com- 
plete growth medium was stimulated by EGF (up to 40% 
stimulation; Fig. 5 4 ,  and furthermore a slightly additive 
growth-stimulatory effect of 0.03 mgiml suramin and EGF was 
observed, reaching the level caused by 0.1 mg/ml suramin 
alone (Fig. 5 4 .  This level could not be attained by the addition 
of EGF alone. Moreover, inhibition of cell proliferation by the 
highest concentration of suramin used (0.3 mg/ml) was unaf- 
fected or only partly abolished by EGF (Fig. 5 4 .  
DISCUSSION 
In the past decade, it has become clear that growth factors 
are involved in the negative or positive growth regulation of a 
variety of cancer types. Until very recently, treatment modali- 
ties based upon growth-factor-receptor interactions, or inter- 
ference with their signal transduction pathways, were not 
available. Evidence that suramin not only inhibits several 
enzyme systems, including reverse transcriptase (De Clerq, 
1987), some other nucleic-acid-related enzymes (On0 et al., 
1979; Spigelman et al., 1987), ATPase (Fortes et al., 1988), and 
protein kinase C (Hensey et al., 1973), but also the binding of 
several growth factors and peptide hormones to their specific 
cell-surface receptors of tumor cells (Betsholtz et al., 1984; 
Garrett et al., 1984; Coffey et al., 1987; Spigelman et aZ., 1987; 
Coughlin et al., 1988; Pollak and Richard, 1990), has made 
suramin the first available growth-factor “antagonist”. More- 
over, pleiotropic actions of suramin on the proliferation of 
various tumor-cell lines in vitro have been described. Suramin 
was stimulatory at low concentrations (50-125 p,g/ml) and 
inhibitory at higher concentrations for some osteosarcoma, 
melanoma, ovarian-carcinoma, bladder-cancer, head-and- 
neck cancer, and breast-cancer cell lines tested (Olivier et al., 
1990). Similar effects were observed for neuroblastoma cells 
(Guo et al., 1990) and for androgen-responsive DDT-1 ham- 
ster ductus deferens tumor cells (Berns et aZ., 1990) (however, 
for these latter cells only in the presence of testosterone) 
(Berns et al., 1990). In the absence of testosterone, suramin 
exclusively caused inhibitory effects on DDT-1 cell prolifera- 
tion (Berns et al., 1990). The studies described here show that, 
provided the concentration used was high enough (> 0.3 
mg/ml), suramin could inhibit the proliferation of 6 different 
human breast cancer cell lines in vitro. The various cell lines 
showed different sensitivities with respect to reversibility of 
suramin action, e.g. for MDA-MB-231 cells a rapid regrowth of 
the cells occurred. This suggests that, for some breast-cancer 
cell lines, suramin is cytostatic rather than cytotoxic, an effect 
which was also observed earlier for androgen-responsive 
LNCaP human prostate-cancer cells (Berns et al., 1990) and 
AKR-2B mouse embryo cells (Coffey et al., 1987). The efficacy 
of the effect of suramin differed markedly for the various 
breast-cancer cell lines studied. Whereas a concentration of, 
e g ,  0.1 to 0.15 mg/ml of suramin in complete growth medium 
containing serum was inhibitory for some cell lines, it was 
stimulatory for others (Fig. 1). From data presented in the 
literature and from our experiments, it is clear that suramin is 
far from being specific to a certain type of growth-factor 
receptor pathway. Moreover, the efficacy with which suramin 
can block the binding of different growth factors to their 
specific receptors and influence cell proliferation varies widely, 
and is also dependent on the density of the cell cultures 
(Olivier et al., 1990). Concentrations of suramin causing 50% 
inhibition of growth factor binding ranged from -~0.03 mg/ml 
for bFGF binding, through k0.04 mg/ml for TGF-P binding, 
to *0.5 mg/ml for EGF binding (Coffey et al., 1987). The 
inhibition of growth-factor-stimulated mitogenicity by suramin 
appeared to be directly correlated to the concentration of 
suramin required to inhibit the binding of these growth factors 
(Coffey et al., 1987). Other studies also showed a wide 
concentration range in which suramin interfered in the binding 
of growth factors (PDGF, FGF, IGF-1, IL-2) to their receptors 
(Betsholtz et al., 1984; Garrett et al., 1984; Coughlin et al., 
1988; Pollak and Richard, 1990; Mills et al., 1990). 
Our study shows that, under serum-free conditions, suramin 
could inhibit both the basal and IGF-1-, bFGF- and estradiol- 
stimulated proliferation of breast cancer cells. In addition, 
increasing concentrations of these mitogens (partly) abolished 
the growth inhibition caused by lower concentrations of 
suramin (Fig. 3a,b). Regarding the effects of IGF-1 and 
bFGF, we suggest that suramin bound, at least in part, to these 
proteins, thus preventing their mitogenic action. With respect 
to the nullifying effect of estradiol on the inhibition of 
basal-cell proliferation caused by suramin, we suggest that 
SURAMIN AND BREAST CANCER CELL GROWTH 
1.0- 
0 .5 -  
1 .s 
1 .o 
0.5 
0.0 
2.5 
2.0 
1.5 
1 .o 
0.5 
0.0 
P 2-----J 
MCF-7 A 
a c o  1 2 3 
Log /GF- 7 170 ng/m/j 
ZR 75.1 C 
I 
c ’  0 1 2 3 
Log EGF/ng/m/j 
1.5 MCF-7 
0.0 ’ ’ 1 
c ’  0 1 2 3 
2.5 
2.0 
1.5 
1 .o 
0.5 
0.0 
Log Esrradiol f7OpMj 
ZR/HERc D 
c ‘  0 1 2 3 
Log EGf  /ng/m/j 
443 
FIGURE 5- Effects of IGF-1, EGF or estradiol on suramin-affected proliferation of breast cancer cells. MCF-7 cells were plated at a 
density of 5,000 cells/200 PI and ZR 75.1 and ZR/HERc cells at a density of 2,500 cells/200 r*.l in their respective complete growth 
medium. After 24 hr, fresh complete growth medium with and without 0.01, 0.1, 1.0, and 10 pgirnl IGF-1 (MCF-7; n), with and without 
0.01, 1, and 10 nM estradiol (MCF-7; b), or with and without 0.001, 0.01, 0.1, and 1 p.g/ml EGF ZR 75.1 and ZR/HERc; c and d, 
respectively) was added. MCF-7 cells were cultured in the absence (0)  and presence of 0.1 (O) ,  0.25 [A), or 0.5 mg/ml suramin (W). ZR 
75.1 and ZR/HERc cells were cultured in the absence (A) and presence of 0.03 O),  0.1 (O), or 0.3 mg/ml suramin (W). Medium was 
refreshed at day 3, and the MTT assay was performed on day 5. The results are 6 epicted as the fraction of control-cell proliferation ? 
standard error of the quotient vs. the log IGF-1 [lo ng/ml] (a), log estradiol [lo pM] (b), or log EGF [ngiml] (c and d )  added. “C” 
indicates cell proliferation in the absence of added respective hormone or growth factors, and the horizontal dotted line in each panel 
represents basal-cell proliferation in complete growth medium. 
estradiol stimulated the secretion of growth-stimulatory growth 
factors which subsequently abrogated the effect of suramin. 
In serum-containing medium, IGF-1 and estradiol were able 
to abolish the inhibition of proliferation caused by suramin 
(Fig. 5 4  b). In complete growth medium, IGF-1 did not affect 
the proliferation of the already maximally proliferating MCF-7 
cells. The inhibition of cell proliferation caused by suramin was 
prevented by the simultaneous addition of IGF-1 in a dose- 
dependent manner, suggesting that IGF-1 was able to replace 
suramin-blocked mitogens (IGF-1, insulin, o r  unidentified 
growth factors) present in the serum. Regarding the nullifying 
effect of estradiol on inhibition of cell proliferation caused by 
suramin, a dose-dependent relationship was less clear and 
maximal restoration was already obtained at a concentration of 
10 pM estradiol. This may be explained by the production of a 
secretory growth stimulating factor(s) whose synthesis is estro- 
gen-dependent and which is already produced at maximal 
levels once the estradiol-receptor pathway has been activated. 
Due to the fact that suramin interferes with different 
efficacies in the binding of various growth-stimulatory and 
growth-inhibitory growth factors to their cell-surface recep- 
tors, the observed differences in sensitivity of the various 
breast-cancer cell lines towards suramin probably depend on 
the phenotype of specific known and as yet unknown growth- 
factor receptors of the various cell lines. The growth- 
stimulatory effects of low concentrations of suramin (below 
0.25 mg/ml) on the proliferation of several of the breast- 
cancer cell lines studied herein (Fig. 1) may have important 
consequences in the treatment of patients with breast cancer. 
In the treatment of patients, and using a loading dose of 350 
mg/m2/day (Stein et al., 1989; LaRocca et aZ., 1990; Klijn et aZ., 
1990) to reach a plasma level of 2280 pg/ml of suramin after 
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10 days (Klijn et aZ., 1990), a growth stimulation of some 
specific breast tumors may initially occur. The stimulation 
observed in vitro, and which may also occur in patients, may 
result from nullifying effects of growth-inhibitory factors, e.g. 
of TGF-P, the binding of which is very effectively blocked by 
very low concentrations of suramin (Coffey et al., 1987). In 
addition, growth stimulation may be caused by potentiating the 
growth-stimulatory effects of specific growth factors, e.g. of 
EGF at low concentrations, as may be inferred from the 
experiment described in Figure 5. The reason for this slightly 
potentiating effect of EGF and low concentrations of suramin 
on the EGF-receptor-containing ZR/HERc cells in particular 
remains at present unclear, but may have resulted from 
effective removal of an unknown molecule from the EGF 
receptor which prevented EGF from fully exerting its mito- 
genic action, or by blockade of the action of a growth- 
inhibitory factor. 
In conclusion, suramin acts as a non-specific growth-factor 
antagonist for breast-cancer cells. At concentrations approach- 
ing the critical plasma concentration in patients (a300 pg/ml) 
suramin is effective in inhibiting breast-cancer cell prolifera- 
tion in vitro. However, in the treatment of breast-cancer 
patients, unwanted effects may arise and growth stimulation of 
some breast cancers may occur as a result of low suramin 
concentrations during the loading phase with suramin, or when 
plasma levels decrease below certain concentrations for weeks 
after one course of treatment (Klijn et al., 1990). 
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